An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation

Neurology. 2018 Feb 6;90(6):289-291. doi: 10.1212/WNL.0000000000004921. Epub 2018 Jan 10.

¹ From The Children's Hospital at Westmead (K.K., S.B., P.B., R.C.D.), University of Sydney; Royal Prince Alfred Hospital (S.C., L.W.); Sydney Children's Hospital (A.J.), Australia; University College London (P.A.B.), Great Ormond Street Institute of Child Health; Manchester Academic Health Science Centre (G.I.R., Y.J.C.), University of Manchester, UK; and INSERM UMR1163 (Y.J.C.), Institute Imagine, Paris, France.
² From The Children's Hospital at Westmead (K.K., S.B., P.B., R.C.D.), University of Sydney; Royal Prince Alfred Hospital (S.C., L.W.); Sydney Children's Hospital (A.J.), Australia; University College London (P.A.B.), Great Ormond Street Institute of Child Health; Manchester Academic Health Science Centre (G.I.R., Y.J.C.), University of Manchester, UK; and INSERM UMR1163 (Y.J.C.), Institute Imagine, Paris, France. russell.dale@health.nsw.gov.au.

No abstract available

Publication types